InhaleRx to Focus on Breakthrough Cancer Pain for Phase 2 Trial of Cannabinoid Analgesic

InhaleRx (ASX:IRX) decided to focus on addressing breakthrough cancer pain as its primary target for an upcoming phase two clinical trial investigating the use of inhalable fixed-dose cannabinoid anal

MT NewswiresJan 10 00:59 ET

InhaleRx Secures Nearly AU$550,000 R&D Tax Incentive Prepayment

Healthcare company InhaleRx (ASX:IRX) entered into a non-dilutive funding agreement with Radium Capital for AU$545,830 to provide early access to a part of the research and development tax incentive E

MT NewswiresDec 21, 2023 03:41 ET

InhaleRX Completes Phase One Trial for Pain Medication Device

InhaleRX (ASX:IRX) completed the phase one trial for its combination medication and device IRX211, the healthcare firm said on Monday. The study investigated the safety and pharmacokinetic profile of

MT NewswiresDec 4, 2023 02:22 ET

InhaleRx Files Ethics Application for Panic Disorder Trial

InhaleRx (ASX:IRX) filed an ethics application with the independent non-profit Bellberry Human Research Ethics Committee for an upcoming phase 2a clinical trial, the medical firm said on Wednesday. Th

MT NewswiresOct 17, 2023 23:23 ET